The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma.

Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects.